Everbridge Unveils COVID-19 ‘Return to Work’ Software Solution to Help Businesses and Governments Improve Safety for Employees and Citizens as They Integrate Back to Public Spaces
5.5.2020 14:00:00 EEST | Business Wire | Press release
Everbridge, Inc. (NASDAQ: EVBG), the global leader in critical event management (CEM), today unveiled its COVID-19 Return to Work software solution to help businesses and governments navigate the unprecedented complexity of operating during the next phase of the COVID-19 pandemic – preparing to bring back the workforce and reopen society.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200505005390/en/
Everbridge COVID-19 Return to Work software solution
As the industry leader in critical event management solutions, Everbridge serves over 5,000 enterprise customers, 1,500 healthcare entities, 3,700 first responder agencies, and the populations of entire states and countries around the world. As organizations pivot to get back to normal activity, Everbridge’s new Return to Work solution enables businesses to manage the complexity of diverse city, state, and country guidelines and mandates that will evolve dynamically over time, as well as ensures compliance with a full audit trail. Everbridge helps businesses manage all of this complexity through real-time risk intelligence, based on 22,000 data sources across 175 countries, that tracks everything from virus hotspots and travel restrictions, to quarantines and states of emergency, to production stoppages and resumptions, to protests and civil unrest.
The new Everbridge Return to Work solution speeds up contact tracing efforts by providing an automated approach to tracking an individual’s exposure to the virus at work, drawing upon 225 pre-existing, out-of-the-box integrations with such systems as calendaring applications, corporate travel itineraries, building access control, and visitor management. Everbridge enables over 100 communication modalities, including its mobile app, to communicate with and provide real-time feedback from employees, such as wellness checks, which can be used to determine who are candidates to return to work. Overall, Everbridge digitizes and automates the end-to-end return-to-work process while dramatically improving the response time to prevent unnecessary exposure to the virus when days and even hours matter.
Health organizations such as The Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) recommend that return to work best practices should require employers to monitor employee health through testing, wellness checks and self-reporting (where employees identify how they are feeling through an app, such as the Everbridge mobile app, on an ‘opt-in’ basis). Contact tracing seeks to identify who else has been exposed to the virus and to coordinate isolation and communications.
“The world’s recovery from the COVID-19 pandemic will be complex, staggered and unpredictable,” said Ajay Nigam, Chief Product Officer at Everbridge. “In the meantime, technology, tools and data are available now to protect people as they return to work, get operations going, and to help governments keep their citizens safe in a better and more efficient manner while protecting privacy. The better handle an organization has on all this complexity, the sooner businesses can return employees to work while governments safely reopen public spaces.”
“As we return to work, it is clear that business is at the forefront of managing the pandemic,” said Nick Allan, CEO at leading specialist risk consultancy, Control Risks. “To keep people safe and a company operating successfully, any international organization will require detailed situational awareness to adhere to diverse and shifting guidelines across potentially hundreds of regions.”
Everbridge’s Return to Work software solution empowers organizations to:
- Automatically leverage the right intelligence, including changing government regulations such as quarantines, curfews, travel bans, new public health policies, and rapidly identify new disease outbreaks.
- Implement, manage and track the tasks for the right protocol at the right location and at the right time, e.g., testing, automated polling of employees or citizens, and enabling mobile wellness checks.
- Accelerate contact tracing by automating the discovery of symptomatic or infected workers – identifying the meetings, buildings, visitors they came in contact with – and mapping against prior travel. Prevent future infections by proactively warning individuals before they enter an incident zone, e.g. an infection hot spot such as an area near a hospital or nursing home, or countries experiencing an increase in outbreaks. Leverage special needs registries to note vulnerable individuals most in need of isolation protocols.
- Integrate polling data from employees or citizens – including results from wellness checks and safety check-ins – into decisions on who can return to work or public spaces.
- Automatically identify and manage impacts to specific assets, supply chain, and transportation routes by tracking production stoppages, closures, and civil unrest, all with a complete audit trail.
- Everbridge also enables governments to anonymously report on crowd movement and population density, without compromising privacy, in order to determine whether groups have achieved more critical mass than is permitted under distancing guidelines, and to verify the success of evacuation efforts.
For city, state, and national governments, Everbridge provides population alerting, incident zone management and citizen polling at country-wide scale, ensuring policies and restrictions are communicated as situations change; aggregates the most comprehensive risk intelligence from the Everbridge Network of public safety, healthcare, transportation and homeland security agencies; quickly ensures evacuations and dispersals have been followed; anonymously monitors crowd movements and previous possible virus exposure of citizens without requiring an app download or infringing privacy.
The Norwegian Directorate for Health, for example, sent a record 5.4 million COVID-19 messages via the Everbridge platform last month to every mobile phone in Norway. The Directorate also sent messages to all non-Norwegian phones roaming inside the country in English, French, German, Spanish, Polish and Russian, providing critical instructions for foreign nationals. Everbridge Public Warning automatically detected the nationality of a person’s mobile device, without the need for any personally identifiable information (PII), and then sent messages in the appropriate language to improve the effectiveness of communication to visitors and international travelers.
The Everbridge Return to Work software solution is immediately available in all markets where Everbridge operates for both corporate and government use cases. To inquire about how an organization can access these tools, please visit Coronavirus Preparedness Hub.
As the global leader in critical event management and public warning, Everbridge and its global platform reach over 550 million people across the world while serving leading F500 companies as well as cities, states, and entire countries.
In response to COVID-19, the Everbridge platform has delivered over 300 million communications specific to coronavirus as well as launched its COVID-19 Shield rapid deployment templates to protect people and maintain operations amid the pandemic. Everbridge also partners with the U.S. Army to mitigate the impact of COVID-19 across over 400 military locations in 70 countries. The company provides daily updates on its Coronavirus Preparedness Hub.
Everbridge also recently announced its “Coronavirus: the Road to Recovery” virtual leadership summit to be held May 20-21, 2020. The conference will feature two marquee keynote speakers: General Colin L. Powell, USA (Ret.), who will speak about leadership in challenging times, and Scott Gottlieb, M.D., former FDA Commissioner, who will discuss a roadmap to recovery. To register and learn more, go to Coronavirus: the Road to Recovery.
About Everbridge
Everbridge, Inc. (NASDAQ: EVBG) is a global software company that provides enterprise software applications that automate and accelerate organizations’ operational response to critical events in order to keep people safe and businesses running. During public safety threats such as active shooter situations, terrorist attacks or severe weather conditions, as well as critical business events including IT outages, cyber-attacks or other incidents such as product recalls or supply-chain interruptions, over 5,000 global customers rely on the company’s Critical Event Management Platform to quickly and reliably aggregate and assess threat data, locate people at risk and responders able to assist, automate the execution of pre-defined communications processes through the secure delivery to over 100 different communication devices, and track progress on executing response plans. The company’s platform sent over 3.5 billion messages in 2019 and offers the ability to reach over 550 million people in more than 200 countries and territories, including the entire mobile populations on a country-wide scale in Australia, Greece, Iceland, the Netherlands, New Zealand, Peru, Singapore, Sweden, and a number of the largest states in India. The company’s critical communications and enterprise safety applications include Mass Notification, Incident Management, Safety Connection™, IT Alerting, Visual Command Center®, Public Warning, Crisis Management, Community Engagement™ and Secure Messaging. Everbridge serves 8 of the 10 largest U.S. cities, 9 of the 10 largest U.S.-based investment banks, 47 of the 50 busiest North American airports, 9 of the 10 largest global consulting firms, 7 of the 10 largest global auto makers, all 4 of the largest global accounting firms, 9 of the 10 largest U.S.-based health care providers, and 6 of the 10 largest technology companies in the world. Everbridge is based in Boston and Los Angeles with additional offices in Lansing, San Francisco, Abu Dhabi, Beijing, Bangalore, Kolkata, London, Munich, New York, Oslo, Singapore, Stockholm and Tilburg. For more information, visit www.everbridge.com, read the company blog, and follow on LinkedIn, Twitter, and Facebook.
Cautionary Language Concerning Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding the anticipated opportunity and trends for growth in our critical communications and enterprise safety applications and our overall business, our market opportunity, our expectations regarding sales of our products, our goal to maintain market leadership and extend the markets in which we compete for customers, and anticipated impact on financial results. These forward-looking statements are made as of the date of this press release and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as “expect,” “anticipate,” “should,” “believe,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “could,” “intend,” variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control. Our actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: the ability of our products and services to perform as intended and meet our customers’ expectations; our ability to successfully integrate businesses and assets that we may acquire; our ability to attract new customers and retain and increase sales to existing customers; our ability to increase sales of our Mass Notification application and/or ability to increase sales of our other applications; developments in the market for targeted and contextually relevant critical communications or the associated regulatory environment; our estimates of market opportunity and forecasts of market growth may prove to be inaccurate; we have not been profitable on a consistent basis historically and may not achieve or maintain profitability in the future; the lengthy and unpredictable sales cycles for new customers; nature of our business exposes us to inherent liability risks; our ability to attract, integrate and retain qualified personnel; our ability to maintain successful relationships with our channel partners and technology partners; our ability to manage our growth effectively; our ability to respond to competitive pressures; potential liability related to privacy and security of personally identifiable information; our ability to protect our intellectual property rights, and the other risks detailed in our risk factors discussed in filings with the U.S. Securities and Exchange Commission (“SEC”), including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on February 28, 2020. The forward-looking statements included in this press release represent our views as of the date of this press release. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
All Everbridge products are trademarks of Everbridge, Inc. in the USA and other countries. All other product or company names mentioned are the property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200505005390/en/
Contact information
Media:
Jeff Young
Everbridge
jeff.young@everbridge.com
781-859-4116
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
